NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.
NeuroDerm Announces 2015 Annual General Meeting of Shareholders
NeuroDerm Ltd. today announced that it will hold its 2015 Annual General Meeting of Shareholders on Thursday, October 29, 2015. > Read More
NeuroDerm Announces Second Quarter 2015 Financial Results and Provides Corporate Update
Company to Host Conference Call and Webcast Today at 8:30 a.m. ET .”> Read More
NeuroDerm to Host Second Quarter 2015 Financial Results Conference Call on August 6, 2015
Management will host a conference call beginning at 8:30 a.m. Eastern Time that day to review results and provide a company update. ”> Read More